Arbutus Biopharma (ABUS) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020 7:30 AM ESTResults from an ongoing Phase 1a/1b clinical trial for Arbutus AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference
Clinical collaboration with Assembly Biosciences, Inc. established to evaluate Arbutus AB-729 in combination with vebicorvir, Assemblys oral core/capsid inhibitor
AB-836, Arbutus oral capsid inhibitor, remains on track for completion of CTA/IND-enabling studies by the end of 2020
Conference Call and... More
